Search

Your search keyword '"Noy, Ariela"' showing total 652 results

Search Constraints

Start Over You searched for: Author "Noy, Ariela" Remove constraint Author: "Noy, Ariela" Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
652 results on '"Noy, Ariela"'

Search Results

1. Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial

2. Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes

3. Author Correction: Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial

6. Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP

9. Retrospective characterization of nodal marginal zone lymphoma

10. TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy

11. Brentuximab vedotin with AVD for stage II–IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial

12. Primary lymphoma of the breast: A report of two cases.

14. Genetic subgroups inform on pathobiology in adult and pediatric Burkitt lymphoma

15. Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial

18. Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era

19. Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis

20. Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies

22. Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma

23. Castleman disease patients report mild COVID-19 symptoms and mount a humoral response to SARS-CoV-2 vaccination

24. Risk of Cancer among Commercially Insured HIV-Infected Adults on Antiretroviral Therapy.

25. Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma

26. Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: The BMT CTN-0903/AMC-080 Trial

31. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study

34. Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-R

35. Diffuse large B-cell lymphoma involving osseous sites: utility of response assessment by PET/CT and good long-term outcomes

36. TP53mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy

37. P1220: EXPLORING TP53 BIOLOGY IN DIFFUSE LARGE B-CELL LYMPHOMA: A GENOMIC AND TRANSCRIPTOMIC META-ANALYSIS

38. Brentuximab vedotin with AVD for stage II–IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial

39. Burkitt Lymphoma

40. Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma

42. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups

43. Gemcitabine plus pembrolizumab after checkpoint blockade failure as a strategy in multiply relapsed Hodgkin lymphoma.

46. Predictors of SARS-CoV-2 Omicron breakthrough infection after receipt of AZD7442 (tixagevimab-cilgavimab) for pre-exposure prophylaxis among hematologic malignancy patients

47. Supplementary Methods, Supplementary Tables 1 through 7, and Supplementary Figures 1 through 7 from Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma

48. Data from Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma

49. Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma

50. Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial

Catalog

Books, media, physical & digital resources